Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 9;316(9):665.
doi: 10.1007/s00403-024-03402-5.

Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel

Megan H Trager #  1 , Alyce M Kuo #  2 , Stephen W Dusza  2 , Vivian Park  3 , Larisa Geskin  1 , Autumn Guyer  4 , Nour Abuhadra  5 , Ayca Gucalp  5 , Mario E Lacouture  6   7   8
Affiliations

Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel

Megan H Trager et al. Arch Dermatol Res. .

Abstract

Paclitaxel is one of the first-line treatments for breast, ovarian, and lung cancers. However, its use is limited by the high frequency of hypersensitivity reactions. In this retrospective chart review at Memorial Sloan Kettering Cancer Center, we assess clinical factors associated with immediate and delayed hypersensitivity reactions to paclitaxel and characterize delayed hypersensitivity reactions to paclitaxel in patients with breast cancer. 12,274 patients were treated with paclitaxel. 6,165 had breast cancer and 1,233 were seen by a dermatologist. 734 patients (11.9%) developed an immediate hypersensitivity reaction. Age (p < 0.001), race (p < 0.001), and prior history of allergy (p = 0.05) were associated with immediate hypersensitivity reactions. 147 patients (4.0%) had a rash of interest. The most common phenotypes were maculopapular (52%) and urticaria (36%). Race (p < 0.001) and history of allergy (p < 0.001) were associated with development of a cutaneous reaction. Patients with an immediate hypersensitivity reaction were more likely to have developed a delayed cutaneous reaction (OR = 1.80). Risk factors for development of immediate hypersensitivity reactions in this study were younger age, race, and history of allergy. Patients who developed an immediate hypersensitivity reaction were more likely to develop a delayed hypersensitivity reaction. Risk factors for development of the rash included Asian race and history of allergy. Identification of risk factors is critical to guide care coordination. Awareness of these clinical factors which are associated with development of a rash could guide providers in choosing treatment with paclitaxel or nab-paclitaxel. If the cutaneous reactions are bothersome to the patient, the transition of treatment from paclitaxel to nab-paclitaxel may be warranted, or a consideration of re-challenge or desensitization may be discussed.

Keywords: Allergy; Breast cancer; Hypersensitivity reaction; Paclitaxel; Rash.

PubMed Disclaimer

References

    1. Kampan NC et al (2015) Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int, 2015: p. 413076
    1. Banerji A et al (2014) Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2(4):428–433 - DOI - PubMed
    1. Demoly P et al (2014) International Consensus on drug allergy. Allergy 69(4):420–437 - DOI - PubMed
    1. Markman M et al (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1):102–105 - DOI - PubMed
    1. Picard M et al (2016) Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 137(4):1154–1164e12 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources